Sydney - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, is sponsoring the ChinaTrials13 conference and will have teams from Novotech’s China offices attending to support biotechs planning clinical trials in China and the Asia-Pacific region (11-21, November 2021).
The conference brings together China biotechs as well as regional and international firms looking to expedite quality trials.
Of particular focus is oncology research. According to GlobalData, China has the highest incidence of cancer in the world, accounting for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020.
Meet the Novotech team at Booth: #11&12
Presentations by Novotech
Workshop: Navigating the Future of Cell Therapies Development: Unlocking the Full Potential
10th November, 9am – 12pm
Topics include:
- CAR-T Therapy: Key considerations during clinical development
- Execution and quality management for cell therapy clinical development
- Statistical considerations in CAR-T therapy clinical trials
Key Novotech experts along with industry leaders will present, then open up for discussions around key issues.
Some of the topics covered at the conference include:
- The Next Phase of Chinese Innovative Biotech Drug Development
- China+US Development: Should You File Your IND in the US Before/After or Simultaneously Alongside Your China IND?
- China CMO Roundtable: What's On the Minds of China's Top CMO's?
- Decentralized Clinical Studies: How COVID-19 Changed Clinical Development & Lessons Learned
- Regulatory Insights: Taking Advantage of Fast Track Channels
- MNC Perspectives: China's New Role in Global Development
- Global Drug Development 2.0: Borderless Innovation
- Cell & Gene Therapy Drug Development in China: What's Next?
- Experience Sharing: China Biotech + MNC Pharma Drug Development Partnerships
- Digital Technology to Support Remote Inspection to Accelerate Clinical Research: PI, Site and Sponsor Perspectives
- Choosing the Right Clinical Development Strategy to Optimize Regulatory Approval Pathway
- Win From the Start: Early Clinical Research Strategies for Innovative Drugs
- Strategy & Planning of Innovative Drugs in MRCT
- How to Design Trials to Better Serve the Needs of Clinical & Needs of Patients
- Strategies for Moving Quickly from Phase I to Phase II
- Seamless Global Development from Phase I to III: A Tale of COVID-19 Antibody Cocktail Therapy
- Real World Data: The Road to Bringing Innovative Therapies to Patients Faster?
Media contact
Toyna Chin
Novotech 기업 소개 Novotech-CRO.com
1997년에 설립된 노보텍은 글로벌 full-service CRO로서, 바이오텍과의 파트너십을 통해 임상의 모든 단계에서 혁신적이고 새로운 치료제 개발을 가속화하는 데 주력하고 있습니다.
CRO 업계를 선도한 공로를 인정받은 노보텍은 2024 Frost & Sullivan Global Biotech CRO Award, 2024 Employer of Choice, 2024 Great Place to Work 미국, 2024 Brandon Hall Gold Award, 2023 CRO Leadership Award, 2023 Asia Pacific Cell & Gene Therapy Clinical Trials Excellence, 그리고 2006년부터 Asia-Pacific Contract Research Organization Company of the Year Award 등 다수의 권위 있는 상을 수상하였습니다.
노보텍은 연구소, 임상 1상 시험기관, 신약 개발 컨설팅 서비스, FDA 규제 전문성을 갖춘 임상 CRO 기업으로, 1상부터 4상까지의 임상시험과 생물학적 동등성 연구를 포함하여 5,000건 이상의 임상 프로젝트에 참여한 경험이 있습니다. 노보텍은 전 세계에 걸쳐 34개의 오피스와 3,000명 이상의 직원을 보유하고 있으며, 신뢰할 수 있는 완전한 형태의 전략적 파트너입니다.
더 자세한 정보나 전문가 팀에게 문의를 원하시면 회사 홈페이지(www.Novotech-CRO.com)를 방문해 주시기 바랍니다.